Rubiadin 1-methyl ether
Catalog No: CFN97227
Rubiadin-1-methyl ether probed as Type I photosensitizers. Rubiadin 1-methyl ether decreases the number of parasites (schizonts) in a dose-dependent manner, and 100% of inhibition was obtained with 30 to 40 micrograms. Rubiadin-1-methyl ether shows strong enhancing activity for adipocyte differentiation, it could be beneficial in the treatment of diabetes. Rubiadin-1-methyl ether has therapeutic potential against osteoporosis, it can promote osteoblast proliferation and inhibit osteoclast TRAP activity and bone resorption, and the inhibitory effects on osteoclastic bone, antiosteoporotic activity of M. officinalis .
Khellin
Catalog No: CFN97303
Khellin, as photosensitizer, together with ultraviolet A (UVA) irradiation, it can treat vitiligo patients; it does not induce skin phototoxicity with UVA but it induces repigmentation similar to psoralens. Khellin exhibits significant Epidermal Growth Factor Receptor (EGFR) inhibitory activity, it has anti-inflammatory, and analgesic properties, it may be beneficial in the management of kidney stone disease caused by hyperoxaluria.
Hypocrellin A
Catalog No: CFN92439
Hypocrellin A, an a natural perylene quinine photosensitizers (PSs), can chelate with heavy metal ions, including Au(III) and Pt(IV), to form a 1:2 complex. Hypocrellin A has light-induced antitumor,antifungal and antiviral activities, it also exerts immunomodulatory effects on MHC-restricted presentation of antigen.
